Psoriasis Redefined Webinar Series

Orbit 360 enabled
Off

A series of two CPD certified modules, presented by recognised experts in clinical psoriasis to support you should you decide to use BIMZELX® ▼ (bimekizumab) for treating your eligible adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Orbit 360 enabled
Off
Orbit 360 enabled
Off
Off

The BIMZELX®  Difference

paragraph-section-webinars

Psoriasis Redefined webinar 1

The BIMZELX®  Difference
Learn & discover
Describe the importance of both IL-17F and IL-17A in the pathogenesis of psoriasis
Explain how dual-inhibition of IL-17F and IL-17A with BIMZELX® affects both IL-17 and IL-23 pro-inflammatory pathways in psoriasis
Recall key data on efficacy, durability and tolerability from the extensive BIMZELX® clinical trial programme in patients with plaque psoriasis
Recognise the BIMZELX® enhanced Patient Support Programme
View module
zoom button Click to enlarge
Presenters
  • Professor Richard Warren
  • Stevan Shaw (UCB)
  • Dr Kave Shams
  • Lucy Moorhead
Keep track of your progress
Login or Register to download your CPD certificate and Learning Guide
Duration
39:19 minutes
Date of preparation: February 2023 | IE-P-BK-PSO-2200032
On

The BIMZELX®  Experience

paragraph-section-webinars

Psoriasis Redefined webinar 2

The BIMZELX®  Experience
Learn & discover
Understand the unmet needs of patients with psoriasis
Identify which patient characteristics may benefit from BIMZELX® and why
View module
zoom button Click to enlarge
Presenters
  • Professor Richard Warren
  • Professor Anthony Bewley
  • Dr Amy Foulkes
Keep track of your progress
Login or Register to download your CPD certificate and Learning Guide
Duration
27:55 minutes
Date of preparation: February 2023 | IE-P-BK-PSO-2200032
On
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Click here for Prescribing Information

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: February 2023
IE-P-BK-PSO-2200032